On May 19, Cansino Biologics Inc(688185) announced that the World Health Organization (who) disclosed on its official website on May 19 that the recombinant novel coronavirus vaccine (adenovirus type 5 vector) of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) . Industry insiders said that this is the only Chinese covid-19 vaccine with the third-generation technical route certified by who Eul, and it is also the most important approval of Cansino Biologics Inc(688185) covid-19 vaccine in history.
According to the announcement, the product is constructed by genetic engineering method. With replication defective human type 5 adenovirus as the vector, it can express the S antigen of novel coronavirus. It is intended to prevent diseases caused by novel coronavirus infection. At the same time, it does not contain preservatives, adjuvants and ingredients of animal origin.
The Eul procedure assesses the suitability of new health products in public health emergencies. Its purpose is to provide drugs, vaccines and diagnostic methods as soon as possible in response to emergencies, while respecting strict safety, efficacy and quality standards. The assessment process should weigh the threat posed by the emergency, the benefits of using the product and any potential risks. At the same time, who Eul is a prerequisite for providing vaccines for covid-19 vaccine implementation plan (covax). The list also allows countries to accelerate their respective regulatory approvals to import and manage covid-19 vaccines. The decision to include kweisa in Eul is based on the review of the product's quality, safety, effectiveness data and risk management plan (RMP) by who prequalification (PQ) experts, including regulatory experts from around the world. The final risk benefit assessment is conducted by the Eul technical advisory group (tag).
Cansino Biologics Inc(688185) said that after the product is included in who Eul, the company still needs to conduct commercial negotiations with the intended countries on the future sales of the product. If the subsequent overseas countries increase the purchase and use of the product, it will have a certain positive impact on the performance of the listed company.
